| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral...
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(...
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...